Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 86

1.

Multiplex PCR Based Urinary Tract Infection (UTI) Analysis Compared to Traditional Urine Culture in Identifying Significant Pathogens in Symptomatic Patients.

Wojno KJ, Baunoch D, Luke N, Opel M, Korman H, Kelly C, Jafri SMA, Keating P, Hazelton D, Hindu S, Makhloouf B, Wenzler D, Sabry M, Burks F, Penaranda M, Smith DE, Korman A, Sirls L.

Urology. 2019 Nov 9. pii: S0090-4295(19)30963-X. doi: 10.1016/j.urology.2019.10.018. [Epub ahead of print]

2.

Clinical outcomes in men with prostate cancer who selected active surveillance using a clinical cell cycle risk score.

Kaul S, Wojno KJ, Stone S, Evans B, Bernhisel R, Meek S, D'Anna RE, Ferguson J, Glaser J, Morgan TM, Lieb J, Yan R, Cohen T, Ehdaie B.

Per Med. 2019 Nov;16(6):491-499. doi: 10.2217/pme-2019-0084. Epub 2019 Sep 4.

3.

Specimen Provenance Testing Identifies Contamination That Affects Molecular Prognostic Assay Results in Prostate Cancer Biopsy Specimens.

Wojno L, Minutella C, Moylan D, Bush A, Wojno K.

Urology. 2018 May;115:87-91. doi: 10.1016/j.urology.2018.02.009. Epub 2018 Feb 21.

PMID:
29476774
4.

Prostatectomy-based validation of combined urine and plasma test for predicting high grade prostate cancer.

Albitar M, Ma W, Lund L, Shahbaba B, Uchio E, Feddersen S, Moylan D, Wojno K, Shore N.

Prostate. 2018 Mar;78(4):294-299. doi: 10.1002/pros.23473. Epub 2018 Jan 8.

PMID:
29315679
5.

A Multi-Center Prospective Study to Validate an Algorithm Using Urine and Plasma Biomarkers for Predicting Gleason ≥3+4 Prostate Cancer on Biopsy.

Albitar M, Ma W, Lund L, Shahbaba B, Uchio E, Feddersen S, Moylan D, Wojno K, Shore N.

J Cancer. 2017 Aug 2;8(13):2554-2560. doi: 10.7150/jca.20031. eCollection 2017.

6.

The clinical and economic implications of specimen provenance complications in diagnostic prostate biopsies.

Wojno K, Hornberger J, Schellhammer P, Dai M, Morgan T.

J Urol. 2015 Apr;193(4):1170-7. doi: 10.1016/j.juro.2014.11.019. Epub 2014 Nov 14. Review.

PMID:
25463992
7.

Reduced Rate of Repeated Prostate Biopsies Observed in ConfirmMDx Clinical Utility Field Study.

Wojno KJ, Costa FJ, Cornell RJ, Small JD, Pasin E, Van Criekinge W, Bigley JW, Van Neste L.

Am Health Drug Benefits. 2014 May;7(3):129-34.

8.

The E2F1/DNMT1 axis is associated with the development of AR negative castration resistant prostate cancer.

Valdez CD, Kunju L, Daignault S, Wojno KJ, Day ML.

Prostate. 2013 Dec;73(16):1776-85. doi: 10.1002/pros.22715. Epub 2013 Sep 4.

9.

Repression of androgen receptor transcription through the E2F1/DNMT1 axis.

Valdez CD, Davis JN, Odeh HM, Layfield TL, Cousineau CS, Berton TR, Johnson DG, Wojno KJ, Day ML.

PLoS One. 2011;6(9):e25187. doi: 10.1371/journal.pone.0025187. Epub 2011 Sep 26.

10.

Molecular markers that can be utilized in diet and dietary supplement research.

Moyad MA, Wojno KJ.

Urol Clin North Am. 2011 Aug;38(3):321-4. doi: 10.1016/j.ucl.2011.05.006. Review.

PMID:
21798394
11.

Histotripsy of the prostate: dose effects in a chronic canine model.

Hall TL, Hempel CR, Wojno K, Xu Z, Cain CA, Roberts WW.

Urology. 2009 Oct;74(4):932-7. doi: 10.1016/j.urology.2009.03.049. Epub 2009 Jul 22.

12.

Rational approach to implementation of prostate cancer antigen 3 into clinical care.

Wang R, Chinnaiyan AM, Dunn RL, Wojno KJ, Wei JT.

Cancer. 2009 Sep 1;115(17):3879-86. doi: 10.1002/cncr.24447.

13.

Is residual neurovascular tissue on prostatectomy specimens associated with surgeon intent at nerve-sparing and postoperative quality of life measures?

Bradford TJ, Weizer AZ, Gilbert SM, Dunn RL, Wojno K, Shah R, Wood DP.

Urol Oncol. 2010 Sep-Oct;28(5):487-91. doi: 10.1016/j.urolonc.2008.09.042. Epub 2008 Dec 25.

PMID:
19110450
14.

Body composition and serum prostate-specific antigen: review and findings from Flint Men's Health Study.

Beebe-Dimmer JL, Faerber GJ, Morgenstern H, Werny D, Wojno K, Halstead-Nussloch B, Cooney KA.

Urology. 2008 Apr;71(4):554-60. doi: 10.1016/j.urology.2007.11.049. Epub 2008 Mar 4. Review.

15.

X-linked inhibitor of apoptosis deficiency in the TRAMP mouse prostate cancer model.

Hwang C, Oetjen KA, Kosoff D, Wojno KJ, Albertelli MA, Dunn RL, Robins DM, Cooney KA, Duckett CS.

Cell Death Differ. 2008 May;15(5):831-40. doi: 10.1038/cdd.2008.15. Epub 2008 Feb 8.

16.

BK virus as a cofactor in the etiology of prostate cancer in its early stages.

Das D, Wojno K, Imperiale MJ.

J Virol. 2008 Mar;82(6):2705-14. Epub 2007 Dec 26.

18.

Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo.

Loberg RD, Ying C, Craig M, Day LL, Sargent E, Neeley C, Wojno K, Snyder LA, Yan L, Pienta KJ.

Cancer Res. 2007 Oct 1;67(19):9417-24.

19.

Glutamine tract length of human androgen receptors affects hormone-dependent and -independent prostate cancer in mice.

Albertelli MA, O'Mahony OA, Brogley M, Tosoian J, Steinkamp M, Daignault S, Wojno K, Robins DM.

Hum Mol Genet. 2008 Jan 1;17(1):98-110. Epub 2007 Sep 29.

PMID:
17906287
20.
21.

Perineural invasion is a marker for pathologically advanced disease in localized prostate cancer.

Lee IH, Roberts R, Shah RB, Wojno KJ, Wei JT, Sandler HM.

Int J Radiat Oncol Biol Phys. 2007 Jul 15;68(4):1059-64. Epub 2007 Mar 29.

22.

Expression of the cytoskeleton linker protein ezrin in human cancers.

Bruce B, Khanna G, Ren L, Landberg G, Jirström K, Powell C, Borczuk A, Keller ET, Wojno KJ, Meltzer P, Baird K, McClatchey A, Bretscher A, Hewitt SM, Khanna C.

Clin Exp Metastasis. 2007;24(2):69-78. Epub 2007 Mar 17.

PMID:
17370041
23.

Elevated E2F1 inhibits transcription of the androgen receptor in metastatic hormone-resistant prostate cancer.

Davis JN, Wojno KJ, Daignault S, Hofer MD, Kuefer R, Rubin MA, Day ML.

Cancer Res. 2006 Dec 15;66(24):11897-906.

24.

Prohibitin mutations are uncommon in prostate cancer families linked to chromosome 17q.

White KA, Lange EM, Ray AM, Wojno KJ, Cooney KA.

Prostate Cancer Prostatic Dis. 2006;9(3):298-302. Epub 2006 May 30.

PMID:
16733518
25.

Clonality of sarcomatous and carcinomatous elements in sarcomatoid carcinoma of the prostate.

Ray ME, Wojno KJ, Goldstein NS, Olson KB, Shah RB, Cooney KA.

Urology. 2006 Feb;67(2):423.e5-423.e8.

PMID:
16461109
26.

Inhibition of DNA methyltransferase activity prevents tumorigenesis in a mouse model of prostate cancer.

McCabe MT, Low JA, Daignault S, Imperiale MJ, Wojno KJ, Day ML.

Cancer Res. 2006 Jan 1;66(1):385-92.

27.

Analysis of membrane-bound complement regulatory proteins in prostate cancer.

Loberg RD, Wojno KJ, Day LL, Pienta KJ.

Urology. 2005 Dec;66(6):1321-6.

PMID:
16360477
28.

Genome-wide linkage scan for prostate cancer aggressiveness loci using families from the University of Michigan Prostate Cancer Genetics Project.

Slager SL, Zarfas KE, Brown WM, Lange EM, McDonnell SK, Wojno KJ, Cooney KA.

Prostate. 2006 Feb 1;66(2):173-9.

PMID:
16173044
29.

INSPstI polymorphism and prostate cancer in African-American men.

Claeys GB, Sarma AV, Dunn RL, Zuhlke KA, Beebe-Dimmer J, Montie JE, Wojno KJ, Schottenfeld D, Cooney KA.

Prostate. 2005 Sep 15;65(1):83-7.

30.
31.

Late renal metastasis of endometrial adenocarcinoma.

Gupta C, Wojno KJ, Schervish EW.

J Urol. 2003 Aug;170(2 Pt 1):519. No abstract available.

PMID:
12853814
32.
33.

Pathologic quiz case: a 76-year-old man with abdominal pain and rapidly progressive course.

Bakshi NA, Wojno KJ.

Arch Pathol Lab Med. 2001 Sep;125(9):1251-2. No abstract available.

PMID:
11520286
34.

Analysis of three-dimensional Doppler ultrasonographic quantitative measures for the discrimination of prostate cancer.

Moskalik AP, Rubin MA, Wojno KJ, Bree R, Rubin JM, Fowlkes JB, Montie JE, Manley S, Carson PL.

J Ultrasound Med. 2001 Jul;20(7):713-22.

35.

Analysis of three-dimensional ultrasound Doppler for the detection of prostate cancer.

Moskalik A, Carson PL, Rubin JM, Bree RL, Fowlkes JB, Rubin MA, Wojno K, Manley S, Montie JE.

Urology. 2001 Jun;57(6):1128-32.

PMID:
11377325
37.

Age-specific distribution of serum prostate-specific antigen in a community-based study of African-American men.

Cooney KA, Strawderman MS, Wojno KJ, Doerr KM, Taylor A, Alcser KH, Heeringa SG, Taylor JM, Wei JT, Montie JE, Schottenfeld D.

Urology. 2001 Jan;57(1):91-6. Review.

PMID:
11164150
38.

8pter-p23 deletion is associated with racial differences in prostate cancer outcome.

Washburn JG, Wojno KJ, Dey J, Powell IJ, Macoska JA.

Clin Cancer Res. 2000 Dec;6(12):4647-52.

39.

Decreased galectin-3 expression in prostate cancer.

Pacis RA, Pilat MJ, Pienta KJ, Wojno K, Raz A, Hogan V, Cooper CR.

Prostate. 2000 Jul 1;44(2):118-23.

40.

Bladder neck-sparing modification of radical prostatectomy adversely affects surgical margins in pathologic T3a prostate cancer.

Marcovich R, Wojno KJ, Wei JT, Rubin MA, Montie JE, Sanda MG.

Urology. 2000 Jun;55(6):904-8.

PMID:
10840106
41.

The polymorphic exon 1 androgen receptor CAG repeat in men with a potential inherited predisposition to prostate cancer.

Lange EM, Chen H, Brierley K, Livermore H, Wojno KJ, Langefeld CD, Lange K, Cooney KA.

Cancer Epidemiol Biomarkers Prev. 2000 Apr;9(4):439-42.

42.

8p22 loss concurrent with 8c gain is associated with poor outcome in prostate cancer.

Macoska JA, Trybus TM, Wojno KJ.

Urology. 2000 May;55(5):776-82.

PMID:
10792100
43.

Sex cord-stromal tumors of the testis with entrapped germ cells: a lesion mimicking unclassified mixed germ cell sex cord-stromal tumors.

Ulbright TM, Srigley JR, Reuter VE, Wojno K, Roth LM, Young RH.

Am J Surg Pathol. 2000 Apr;24(4):535-42.

PMID:
10757400
44.

Rapid ("warm") autopsy study for procurement of metastatic prostate cancer.

Rubin MA, Putzi M, Mucci N, Smith DC, Wojno K, Korenchuk S, Pienta KJ.

Clin Cancer Res. 2000 Mar;6(3):1038-45.

45.

Relationship and significance of greatest percentage of tumor and perineural invasion on needle biopsy in prostatic adenocarcinoma.

Rubin MA, Bassily N, Sanda M, Montie J, Strawderman MS, Wojno K.

Am J Surg Pathol. 2000 Feb;24(2):183-9.

PMID:
10680885
46.

Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.

Becker C, Piironen T, Pettersson K, Björk T, Wojno KJ, Oesterling JE, Lilja H.

J Urol. 2000 Jan;163(1):311-6.

PMID:
10604382
47.

Decreased 13-S-hydroxyoctadecadienoic acid levels and 15-lipoxygenase-1 expression in human colon cancers.

Shureiqi I, Wojno KJ, Poore JA, Reddy RG, Moussalli MJ, Spindler SA, Greenson JK, Normolle D, Hasan AA, Lawrence TS, Brenner DE.

Carcinogenesis. 1999 Oct;20(10):1985-95.

PMID:
10506115
48.

Antifibrinolytic additives to fibrin glue for laparoscopic wound closure in urinary tract.

Beduschi R, Beduschi MC, Wojno KJ, Jhung M, Williams AL, Wolf JS Jr.

J Endourol. 1999 May;13(4):283-7.

PMID:
10405907
49.

Characteristics of nonmalignant and malignant human prostate in organ culture.

Varani J, Dame MK, Wojno K, Schuger L, Johnson KJ.

Lab Invest. 1999 Jun;79(6):723-31.

PMID:
10378515
50.

Acute bleeding after allogeneic bone marrow transplantation: association with graft versus host disease and effect on survival.

Nevo S, Enger C, Swan V, Wojno KJ, Fuller AK, Altomonte V, Braine HG, Noga SJ, Vogelsang GB.

Transplantation. 1999 Mar 15;67(5):681-9.

PMID:
10096522

Supplemental Content

Support Center